SECsense Logo

Centessa Pharmaceuticals 8-K Report: Key Insights & Shareholder Updates (Jan 2025)

$CNTA
Form 8-K
Filed on: 2025-01-08
Source
Centessa Pharmaceuticals 8-K Report: Key Insights & Shareholder Updates (Jan 2025)

Based on the analysis of the provided financial report excerpt, here are the key points extracted:

  1. Entity Identification:
  • The reporting entity is Centessa Pharmaceuticals PLC.
  • The SEC CIK (Central Index Key) number is 0001847903.
  1. Report Type and Date:
  • The report is an 8-K, which is a form used to report major events that shareholders should know about.
  • The report date is January 8, 2025.
  1. Share Information:
  • The company’s ordinary shares have a nominal value of £0.002 per share.
  • The American Depositary Shares (ADS) represent one ordinary share and are also traded on NASDAQ under the ticker CNTA.
  1. Geographical and Contact Information:
  • The company is located at 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, GB.
  • Contact phone number is +1 (617) 468-5770.
  1. Stock Classifications:
  • The report includes classifications for common stock and American depositary shares, indicating that both types of equity are part of the company's capital structure.
  1. Taxonomy and Context:
  • The report adheres to XBRL (eXtensible Business Reporting Language) standards, specifically referencing US GAAP (Generally Accepted Accounting Principles) for financial reporting.
  1. Reporting Period:
  • The reporting period for the data presented is January 8, 2025.

Insights:

  • Centessa Pharmaceuticals is actively maintaining compliance with SEC reporting requirements, which is important for investor transparency.
  • The specific mention of ordinary shares and American Depositary Shares suggests a strategy to attract both local and international investors.
  • Understanding the nominal value of shares provides insight into the company’s equity structure and potential valuation.
  • The presence of contact information indicates an openness to investor communications, which can be crucial for investor relations.

Overall, this section of the financial report provides a snapshot of Centessa Pharmaceuticals' equity structure and compliance with regulatory standards as of the specified date.